Literature DB >> 24528917

Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment.

Lana X Tong1, Julie Jackson1, Justin Kerstetter1, Scott D Worswick2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528917     DOI: 10.1016/j.jaad.2013.09.035

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  17 in total

Review 1.  Efficacy of ruxolitinib for myelofibrosis.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2014-05-24       Impact factor: 3.889

Review 2.  Ruxolitinib: a review of its use in patients with myelofibrosis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 3.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

4.  Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.

Authors:  Samantha C Lee; John Feenstra; Paul R Georghiou
Journal:  BMJ Case Rep       Date:  2014-06-02

5.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

6.  Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.

Authors:  Róbert Pálmason; Ola Lindén; Johan Richter
Journal:  BMC Hematol       Date:  2015-07-11

Review 7.  Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors:  A Yacoub; O Odenike; S Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 8.  Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors:  A Pardanani; A Tefferi
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

Review 9.  Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.

Authors:  Jeffrey C Bryan; Srdan Verstovsek
Journal:  Cancer Chemother Pharmacol       Date:  2016-03-26       Impact factor: 3.333

Review 10.  Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Robert Peter Gale
Journal:  Onco Targets Ther       Date:  2015-05-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.